In conclusion, in our study of eyes with ongoing chronic anti-VEGF treatment for wet AMD, we found that switch of anti-VEGF agent from ranibizumab to aflibercept did not affect visual function whereas improvement in retinal morphology was observed and planned treatment intervals were prolonged. This evidence concerns the gene VEGFA and wet macular degeneration.